Across 5 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Humana news is Somewhat Bullish (+43)
on a scale from −100 to +100.
That is up 5 points from the previous 30 days (+38).
📈 Humana raised 2026 EPS forecast to $9.50 on strong Medicare Part D performance.
👥 Early enrollment trends indicate anticipated membership growth for 2027.
Very Bullish +85
What Humana (HUM) Said on Its Q3 Earnings Call - Yahoo Finance
AI-generated analysis
Key insights
📈 Humana raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share from $9 due to favorable Medicare Part D performance and controlled medical costs.
👥 Early Medicare Advantage enrollment trends are ahead of expectations, with the company anticipating membership growth in 2027.
💰 Humana expects material margin improvement next year, targeting an individual Medicare Advantage margin above 3% in 2028.
⭐ Medicare Stars ratings exceeded the top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028.
🤝 A new joint venture with BlackRock reduces the company's cost of capital and lowers its GAAP debt-to-capital ratio by approximately 130 basis points.
💸 The planned sale of its minority interest in Gentiva is expected to generate about $900 million in pretax proceeds during the fourth quarter.
🏥 CenterWell Primary Care added nearly 147,000 members this year, representing 30% growth including the acquisition of MaxHealth.
💊 Medical cost trends for 2026 were at the lower end of expectations, with a health technology pipeline expected to push Part D trend to 14% to 15% in 2027.
📈 Bullish signals
📈Humana raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share from $9, driven by favorable Medicare Part D performance and medical costs at or below expectations.
👥Early Medicare Advantage enrollment trends are ahead of expectations, leading the company to anticipate membership growth in 2027.
💰Humana expects material margin improvement next year, targeting an individual Medicare Advantage margin above 3% in 2028.
⭐Medicare Stars ratings significantly exceeded the top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028.
🤝A joint venture with BlackRock reduces the company's cost of capital and is expected to lower its GAAP debt-to-capital ratio by approximately 130 basis points.
💸The sale of its minority interest in Gentiva is expected to generate about $900 million in pretax proceeds, providing significant liquidity.
🏥CenterWell Primary Care added nearly 147,000 members this year, representing 30% growth and including the first-quarter acquisition of MaxHealth.
💊Medical cost trends for 2026 were at the lower end of expectations, with a health technology pipeline expected to push Part D trend to 14% to 15% in 2027.
Article
Humana Inc. (HUM) raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share, up from a prior expectation of $9, driven by favorable Medicare Part D performance and medical costs that met or exceeded expectations. CEO Jim Rechtin stated the company's recovery trajectory has shifted from on plan to ahead of plan, with early Medicare Advantage enrollment trends indicating membership growth anticipated for 2027.
The health insurer expects material margin improvement in 2027, targeting an individual Medicare Advantage margin above 3% by 2028. Humana's Medicare Stars ratings for the bonus year 2028 significantly exceeded its top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028 as the company plans to invest in Stars capabilities and customer experience.
Humana announced strategic financial moves including a joint venture with BlackRock that reduces its cost of capital and lowers its GAAP debt-to-capital ratio by approximately 130 basis points. Additionally, the company expects to complete the sale of its minority interest in Gentiva during the fourth quarter, generating about $900 million in pretax proceeds, while intending to grow its dividend and increase buybacks as earnings recover.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Humana Inc. (HUM) raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share, up from a prior expectation of $9, driven by favorable Medicare Part D performance and medical costs that met or exceeded expectations. CEO Jim Rechtin stated the company's recovery trajectory has shifted from on plan to ahead of plan, with early Medicare Advantage enrollment trends indicating membership growth anticipated for 2027.
The health insurer expects material margin improvement in 2027, targeting an individual Medicare Advantage margin above 3% by 2028. Humana's Medicare Stars ratings for the bonus year 2028 significantly exceeded its top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028 as the company plans to invest in Stars capabilities and customer experience.
Humana announced strategic financial moves including a joint venture with BlackRock that reduces its cost of capital and lowers its GAAP debt-to-capital ratio by approximately 130 basis points. Additionally, the company expects to complete the sale of its minority interest in Gentiva during the fourth quarter, generating about $900 million in pretax proceeds, while intending to grow its dividend and increase buybacks as earnings recover.
📈 Humana raised 2026 EPS forecast to $9.50 on strong Medicare Part D performance.
👥 Early enrollment trends indicate anticipated membership growth for 2027.
💰 Company targets individual Medicare Advantage margin above 3% in 2028.
⭐ High Stars rating of 4.17 may provide one-time financial tailwind in 2028.
💸 Sale of Gentiva minority interest expected to generate $900 million proceeds.
📈 Humana raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share from $9 due to favorable Medicare Part D performance and controlled medical costs.
👥 Early Medicare Advantage enrollment trends are ahead of expectations, with the company anticipating membership growth in 2027.
💰 Humana expects material margin improvement next year, targeting an individual Medicare Advantage margin above 3% in 2028.
⭐ Medicare Stars ratings exceeded the top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028.
🤝 A new joint venture with BlackRock reduces the company's cost of capital and lowers its GAAP debt-to-capital ratio by approximately 130 basis points.
💸 The planned sale of its minority interest in Gentiva is expected to generate about $900 million in pretax proceeds during the fourth quarter.
🏥 CenterWell Primary Care added nearly 147,000 members this year, representing 30% growth including the acquisition of MaxHealth.
💊 Medical cost trends for 2026 were at the lower end of expectations, with a health technology pipeline expected to push Part D trend to 14% to 15% in 2027.
Bullish Signals
Raised 2026 EPS forecast to $9.50 from $9.
Bullish Signals
Humana raised its full-year 2026 adjusted earnings forecast to at least $9.50 per share from $9, driven by favorable Medicare Part D performance and medical costs at or below expectations.
Early Medicare Advantage enrollment trends are ahead of expectations, leading the company to anticipate membership growth in 2027.
Humana expects material margin improvement next year, targeting an individual Medicare Advantage margin above 3% in 2028.
Medicare Stars ratings significantly exceeded the top-quartile goal with a member-weighted rating of 4.17, potentially providing a one-time financial tailwind in 2028.
A joint venture with BlackRock reduces the company's cost of capital and is expected to lower its GAAP debt-to-capital ratio by approximately 130 basis points.
The sale of its minority interest in Gentiva is expected to generate about $900 million in pretax proceeds, providing significant liquidity.
CenterWell Primary Care added nearly 147,000 members this year, representing 30% growth and including the first-quarter acquisition of MaxHealth.
Medical cost trends for 2026 were at the lower end of expectations, with a health technology pipeline expected to push Part D trend to 14% to 15% in 2027.
Company updateEarnings reportAI-generated analysis
Humana (HUM) is set to report its third-quarter earnings on November 6, amidst the critical window of Medicare Open Enrollment which closes December 7. The company previously disclosed in July that it anticipates approximately 600,000 Medicare Advantage members will lose their plans in 2027, representing roughly 8% of its total base. This strategic reduction targets underperforming plans with low CMS star ratings to improve overall portfolio health.
Beyond plan discontinuations, surviving Humana plans face significant cost increases effective January 1, 2027. The average maximum out-of-pocket limit for medical expenses is projected to rise by approximately 8%, while Part D deductibles are expected to increase by about 30%. These changes impact roughly 6.45 million members in individual Medicare Advantage plans at the end of Q2, altering their financial exposure even if they retain coverage.
Management aims to recapture just over 40% of departing members, or around 240,000 people, into other Humana plans to mitigate revenue loss. The CFO has identified returning to a sustainable margin of at least 3% by 2028 as a top priority. CEO Jim Rechtin noted that recent regulatory changes, such as the end of the Part D premium stabilization demonstration, will negatively impact members more than the company itself.
📅 Q3 earnings released Nov. 6 amid ongoing Medicare Open Enrollment.
📉 Plans to drop ~600,000 members (8%) by 2027.
💰 Surviving plans face ~8% higher out-of-pocket max and ~30% higher Part D deductibles in 2027.
🔄 Expecting to recapture ~40% of departing members into other Humana plans.
🎯 Aiming for sustainable margins of at least 3% by 2028 via exits and cost management.
📅 Humana reports Q3 earnings on Nov. 6, three weeks into Medicare Open Enrollment which closes Dec. 7.
📉 The company plans to drop roughly 600,000 Medicare Advantage members in 2027, representing about 8% of its base.
💰 Surviving Humana plans will see an ~8% increase in the out-of-pocket maximum and ~30% higher Part D deductibles starting Jan. 1, 2027.
🔄 Humana expects to recapture just over 40% of leaving members (approx. 240,000 people) into other Humana plans.
🎯 Management prioritizes returning to a sustainable margin of at least 3% by 2028 through plan exits and cost management.
⚠️ CEO Jim Rechtin stated that CMS decisions ending Part D premium stabilization will impact members more than the company.
📊 Humana is cutting about 2,400 individual Medicare Advantage plan options to improve its portfolio ratings.
Bullish Signals
Recapturing ~40% of departing members (~240k).
Targeting sustainable margins of at least 3% by 2028.
Risk Factors
Anticipates losing 600k members by 2027 (8% of base).
Plans face 8% higher out-of-pocket max and 30% higher Part D deductibles in 2027.
Cutting 2,400 plan options due to low CMS star ratings.
Bullish Signals
Humana expects to recapture just over 40% of departing members (approximately 240,000 people) into other Humana plans.
Management has set a clear financial target to return to a sustainable margin of at least 3% by 2028.
Risk Factors
The company anticipates losing approximately 600,000 Medicare Advantage members in 2027, representing about 8% of its total base.
Surviving Humana plans face an ~8% increase in the out-of-pocket maximum and ~30% higher Part D deductibles effective Jan. 1, 2027.
Humana is cutting approximately 2,400 individual Medicare Advantage plan options to address low CMS star ratings.
Zacks Investment Research highlights Humana Inc. (HUM) as a compelling value stock, noting its current Zacks Rank of #2 (Buy) and an 'A' grade in their proprietary Value category system. The analysis suggests that HUM is being undervalued by the broader market based on fundamental metrics and traditional valuation approaches favored by value investors.
The article details specific financial ratios supporting this valuation thesis, including a Price-to-Book (P/B) ratio of 1.66, which is significantly lower than the industry average of 2.77 and represents an attractive entry point compared to HUM's one-year trading range. Additionally, the company exhibits a low Price-to-Cash-Flow (P/CF) ratio of 12.28 against an industry average of 19.18, indicating strong cash generation relative to its market price.
These metrics, combined with a solid earnings outlook, position HUM as an impressive value opportunity for investors utilizing fundamental analysis. The report concludes that the convergence of these undervaluation signals and positive earnings expectations makes Humana a standout pick within the current market environment.
📈 Humana holds Zacks Rank #2 (Buy) with 'A' Value grade.
💰 HUM trades at P/B of 1.66, below industry average of 2.77.
💵 Price-to-Cash-Flow ratio is 12.28 versus industry average of 19.18.
📉 Stock P/B ranged 1.45 to 2.30 over past year with median 1.82.
🚀 Strong earnings outlook confirms HUM as attractive undervalued investment.
📈 Humana (HUM) holds a Zacks Rank #2 (Buy) designation alongside an 'A' grade in the Value category.
💰 The company trades at a Price-to-Book ratio of 1.66, well below the industry average of 2.77.
💵 HUM's Price-to-Cash-Flow ratio stands at 12.28 compared to an industry average of 19.18.
📉 The stock has traded between P/B ratios of 1.45 and 2.30 over the past year, with a median of 1.82.
🔍 Fundamental analysis suggests HUM is currently undervalued relative to its peers and historical ranges.
🚀 A solid earnings outlook reinforces the company's status as an attractive value investment.
Business restructuringJoint ventureAI-generated analysis
Humana announced a major restructuring of its CenterWell senior-care clinic network, selling majority stakes in approximately 150 clinics to HPS Investment Partners, a subsidiary of BlackRock, for $2.8 billion. The deal is expected to close in the fourth quarter and replaces a previous joint venture with private equity firm WCAS that carried a $2.8 billion debt-like obligation known as a 'put'. By removing this liability, Humana aims to improve its balance sheet, lower its cost of capital, and free up resources for growth investments within the remaining network.
The transaction fundamentally alters the economic upside associated with Humana's high-quality care model. While Humana retains operational control and a minority stake in the clinics, it has ceded majority ownership rights to BlackRock. This structure means that future cost savings generated by keeping patients healthy—specifically the difference between Medicare payments and actual medical costs—will accrue primarily to BlackRock rather than Humana. The deal includes an exit option for BlackRock until 2033, allowing them to force a sale if Humana does not repurchase the assets.
Humana's recent stock surge is driven less by this transaction and more by improved Medicare Advantage star ratings. The company projects that 95% of its members will achieve four or more stars in 2027, up from 20% in 2026, which could generate approximately $4.8 billion in quality bonuses by 2028. However, the long-term viability of this strategy hinges on whether Humana can sustainably control medical costs below Medicare reimbursement rates. If successful, the asset may be worth more than the sale price; if not, the deal represents a significant discount for BlackRock.
The company reaffirmed its guidance for at least $9 in adjusted earnings per share for 2026 despite the restructuring. The strategic implication is that Humana has effectively offloaded the primary engine of its value creation—the CenterWell network—to a patient capital provider like BlackRock. The success of this move depends entirely on the trajectory of Medicare Advantage margins and Humana's ability to maintain profitability without majority ownership of the clinics it operates.
🏥 Sold majority stakes in ~150 clinics for $2.8B debt relief.
📉 Cedes primary cost savings upside to BlackRock on CenterWell.
⭐ Projected 95% star ratings could drive $4.8B quality bonuses by 2028.
💰 Reaffirmed at least $9 adjusted EPS guidance for 2026.
🏥 Humana sold majority stakes in ~150 senior-care clinics to BlackRock's HPS for $2.8B, removing a $2.8B debt-like obligation from its balance sheet.
📉 The deal cedes the primary upside of cost savings and quality bonuses to BlackRock, leaving Humana with only a minority stake in the CenterWell network.
⭐ Improved Medicare Advantage star ratings (projected 95% at 4+ stars in 2027) could generate $4.8B in quality bonuses by 2028, driving recent stock gains.
📅 BlackRock retains exit options until 2033, allowing it to force a sale if Humana does not repurchase the majority of the clinics.
💰 Humana reaffirmed guidance for at least $9 in adjusted earnings per share for 2026 despite the major asset restructuring.
⚖️ The transaction replaces a previous joint venture with private equity firm WCAS, eliminating a 'put' option that required Humana to buy out its stake.
Bullish Signals
Sold CenterWell stakes, removing $2.8B debt-like obligation.
Reaffirmed $9 EPS guidance for 2026 after restructuring.
Projected $4.8B quality bonuses by 2028 from star ratings.
Risk Factors
Majority ownership ceded to BlackRock.
Clinics may be forced sold by 2033.
Cost control success critical for future.
Bullish Signals
Humana removed a $2.8 billion debt-like obligation from its balance sheet by selling majority stakes in its CenterWell clinic network.
The company reaffirmed guidance for at least $9 in adjusted earnings per share for 2026 following the restructuring announcement.
Improved Medicare Advantage star ratings, with 95% of members projected to achieve 4+ stars in 2027, could generate approximately $4.8 billion in quality bonuses by 2028.
Risk Factors
By selling majority stakes, Humana has ceded the primary economic upside from cost savings and quality bonuses to BlackRock, which now holds majority ownership.
The deal structure allows BlackRock to force a sale of the remaining clinics by 2033 if Humana fails to repurchase them, creating long-term asset uncertainty.
The long-term success of the transaction depends entirely on whether Humana can sustainably control medical costs below Medicare payments, as it no longer owns the majority of the delivery network.
Humana (NYSE: HUM) has agreed to a $2.8 billion transaction with BlackRock to restructure ownership of nearly 150 CenterWell Senior Primary Care clinics. This deal replaces Welsh, Carson, Anderson & Stowe as Humana's private equity partner, allowing the insurer to retain operational control while reducing balance sheet liabilities and deferring decisions on acquiring facilities outright. The agreement is expected to close in the fourth quarter of 2026, subject to regulatory approvals.
The transaction significantly improves Humana's financial flexibility by removing investor put options that previously required capital outlays, thereby lowering its cost of capital. While a derivative liability remains due to minimum return protections for BlackRock, the restructuring supports Humana's strategy to expand its clinic portfolio through additional capital deployment and acquisitions over the next two years.
Simultaneously, Humana has recovered from recent declines in Medicare Advantage quality ratings, with approximately 95% of its members now enrolled in contracts rated four stars or higher for 2027. This recovery positions the company to receive substantial government bonus payments starting in 2028, estimated at $4.8 billion by Evercore ISI and an additional $3.6 billion in increased payments by S&P Global Ratings.
🤝 Humana partners with BlackRock for $2.8B CenterWell restructuring to lower capital costs.
⭐ Medicare Advantage quality rebounded to 95% four-star+ contracts by 2027 from 20%.
💰 Rating recovery unlocks ~$4.8B federal bonuses and $3.6B extra payments by 2028.
📈 Shares surged 15% to close at $432.20 following the ratings announcement.
⚖️ S&P affirmed BBB credit rating but kept negative outlook on margin uncertainty.
🤝 Humana partners with BlackRock for a $2.8 billion restructuring of CenterWell clinics, replacing WCAS to reduce liabilities and lower the cost of capital.
📉 The new joint venture removes mandatory investor put options, providing Humana with greater financial flexibility and time to develop its clinic portfolio.
⭐ Humana's Medicare Advantage quality ratings have rebounded sharply, with 95% of members in four-star or higher contracts for 2027 compared to 20% previously.
💰 The rating recovery could unlock approximately $4.8 billion in federal bonus payments and an additional $3.6 billion in increased government payments by 2028.
📈 Humana shares surged roughly 15% following the ratings announcement, closing at $432.20 on October 15.
🏥 CenterWell plans to deploy additional capital over the next two years to support existing clinics and establish new locations through acquisitions.
⚖️ S&P Global Ratings affirmed Humana's BBB issuer credit rating but maintained a negative outlook due to uncertainty about restoring operating margins.
🎯 Humana targets adjusted earnings of at least $9.00 per share for 2026, maintaining its previous guidance despite the restructuring impact on GAAP earnings.
Bullish Signals
Quality ratings hit 95% four-star or higher in 2027.
Estimated $4.8 billion federal bonus payments start in 2028.
BlackRock deal lowers capital costs and aids CenterWell expansion.
Earnings depend on reinvestment in member benefits.
Bullish Signals
Humana's Medicare Advantage quality ratings have recovered dramatically to 95% four-star or higher enrollment in 2027, significantly exceeding industry benchmarks and J.P. Morgan expectations.
The improved ratings position Humana to receive an estimated $4.8 billion in federal bonus payments starting in 2028, alongside an additional $3.6 billion in increased government payments year-over-year.
The BlackRock transaction removes investor put options and reduces balance sheet liabilities, lowering the cost of capital and providing flexibility to expand the CenterWell clinic network.
Humana shares surged approximately 15% on October 9 following the ratings announcement, reflecting strong investor confidence in the company's profitability recovery.
Risk Factors
The restructuring creates a derivative liability due to minimum return protections for BlackRock, which will be measured at fair value and could affect reported GAAP earnings.
Analysts caution that the ultimate earnings contribution from higher Medicare Advantage payments depends on how much Humana reinvests in member benefits and provider agreements.
Humana stock surged approximately 16 percent after hours and closed up 11.47 percent following the release of better-than-expected 2027 Medicare Advantage Star ratings by the Centers for Medicare and Medicaid Services on October 9, 2026. The positive surprise in the ratings removed a significant overhang that had weighed on the company's valuation, separating Humana from managed care peers whose stocks declined during the same event. This market reaction signaled a renewed shift in sentiment regarding Humana's operational strength and its ability to maintain a dominant market position within the sector.
Major institutional investors responded quickly to the news with bullish actions, as Barclays upgraded its rating on Humana to Overweight and raised its price target to $515. Cantor Fitzgerald followed suit, boosting its rating to Overweight with a higher price target of $460, citing confidence in stronger Medicare Advantage margins and future Star ratings. Analysts collectively viewed the ratings reset as a catalyst that provided clarity on Humana's strategic positioning, validating its competitive advantage against rivals like CVS and Alignment Healthcare.
Fundamentally, Humana reported robust financial performance with quarterly revenue of $40.9 billion and net income of $694 million, translating to diluted earnings per share of $5.73. The company maintains a highly conservative balance sheet with a debt-to-equity ratio of just 0.12, generating approximately $1.97 billion in operating cash flow and $1.83 billion in free cash flow for the latest quarter. These strong fundamentals support its strategy of expanding Chronic Condition Special Needs coverage across roughly 2,600 counties while leveraging low premium plans with rich benefits to attract new enrollees.
📈 Shares jumped 16% after hours following better-than-feared 2027 Medicare Advantage Star ratings.
🏆 Barclays upgraded stock to Overweight with $515 price target citing improved margins.
💰 Reported quarterly revenue of $40.9 billion and net income of $694 million.
🛡️ Maintains robust balance sheet with 0.12 debt-to-equity ratio and $1.83B free cash flow.
🚀 Expanding Chronic Condition Special Needs coverage across approximately 2,600 counties.
📈 Humana shares jumped 16 percent after hours and closed up 11.47 percent following the release of better-than-feared 2027 Medicare Advantage Star ratings on October 9, 2026.
🏆 Barclays upgraded Humana to Overweight with a $515 price target, while Cantor Fitzgerald raised its rating and set a $460 target, citing improved margins and strategic positioning.
💰 The company reported quarterly revenue of $40.9 billion and net income of $694 million, demonstrating strong profitability in the managed care sector.
🛡️ Humana maintains a robust balance sheet with a low debt-to-equity ratio of 0.12 and generated $1.83 billion in free cash flow during the latest quarter.
🚀 The insurer is expanding Chronic Condition Special Needs coverage across approximately 2,600 counties to target specific patient segments and manage costs effectively.
📉 While Humana rallied, rivals such as CVS and Alignment Healthcare saw their stocks sell off, highlighting Humana's relative strength in the sector.
💡 The positive ratings reset removed a significant overhang, providing clarity and confidence in Humana's ability to maintain its market position against regulatory uncertainty.
Bullish Signals
Stock surged 16% after hours on better-than-expected 2027 Medicare Advantage Star ratings.
Barclays upgraded to Overweight with $515 price target on contract bonus recovery.
Cantor Fitzgerald raised rating to Overweight with $460 target citing margin growth.
Generated $40.9B revenue and $694M net income proving core business profitability.
Robust balance sheet with 0.12 debt-to-equity ratio handles economic shocks well.
Bullish Signals
Humana stock surged 16 percent after hours and closed up 11.47 percent following the release of better-than-expected 2027 Medicare Advantage Star ratings, signaling a major positive sentiment shift.
Barclays upgraded its rating on Humana to Overweight and raised its price target to $515, betting that key Medicare Advantage contracts will regain bonus status.
Cantor Fitzgerald boosted its rating to Overweight with a $460 price target, highlighting stronger Medicare Advantage margins and future Star ratings as key catalysts for growth.
The company generated substantial quarterly revenue of $40.9 billion and net income of $694 million, proving the core business remains highly profitable despite tight industry margins.
Humana maintains a robust balance sheet with a conservative debt-to-equity ratio of just 0.12, allowing it to handle economic shocks better than many competitors.
The insurer produced $1.97 billion in operating cash flow and $1.83 billion in free cash flow, providing significant liquidity to support sustained uptrends and strategic investments.
Humana is strategically expanding Chronic Condition Special Needs coverage across approximately 2,600 counties to attract new enrollees while retaining existing ones through value-based care.
The company's low price-to-sales ratio of 0.33 suggests the stock looks relatively cheap given its massive revenue stream and growth potential.
Shares of Humana (NYSE:HUM) surged 16.8% in pre-market trading following an upgrade from Robert W. Baird, which changed the rating to Outperform and raised the price target to $596 from $390. The upgrade is driven by a significant operational recovery in federal quality ratings, with 95% of Medicare Advantage members now enrolled in plans rated 4.0 stars or higher for 2027, up from just 25% in the previous cycle.
Baird analyst Michael Ha increased his earnings estimate to over $35 per share for 2028, citing conservative benefit designs, restored Stars performance, and easing medical cost growth as key catalysts. For Medicare Advantage insurers, achieving a four-star rating is critical as it unlocks federal quality bonus payments that fund competitive member benefits and widen underwriting margins.
The stock has already gained 63.3% year-to-date and reached a new 52-week high of $431.94. This recent volatility reflects the market's strong reaction to the news, with Humana having experienced 16 moves greater than 5% over the last year. The upgrade follows a similar positive shift from Barclays 14 days ago, indicating growing Wall Street confidence in the company's strategic position.
📈 Shares jumped 16.8% pre-market after Baird upgraded stock to Outperform with $596 target.
⭐ 95% of Medicare Advantage members now enrolled in plans rated 4.0 stars or higher for 2027.
💰 Analyst raised adjusted EPS forecast to over $35 for 2028 on restored Stars performance.
🏆 Four-star ratings unlock federal quality bonuses funding benefits and improving underwriting margins.
📊 Stock gained 63.3% YTD, setting new 52-week high at $431.94 per share.
📈 Humana shares jumped 16.8% in pre-market trading after Robert W. Baird upgraded the stock to Outperform and raised its price target to $596.
⭐ The company reported that 95% of its Medicare Advantage members are now enrolled in plans rated 4.0 stars or higher for 2027, a massive increase from 25% in the prior cycle.
💰 Baird analyst Michael Ha raised his adjusted earnings per share forecast to over $35 for 2028 based on restored Stars performance and easing medical costs.
🏆 Achieving four-star ratings unlocks federal quality bonus payments that directly fund competitive member benefits and improve underwriting margins for Humana.
📊 The stock has gained 63.3% since the beginning of the year and set a new 52-week high at $431.94 per share.
🔄 This upgrade follows a similar positive rating change from Barclays, suggesting a broader shift in Wall Street's view of Humana's operational recovery.
Bullish Signals
Baird upgraded to Outperform with $596 price target.
95% MA members in 4.0+ star plans by 2027.
EPS projected above $35 in 2028 per Ha.
Restored stars unlock federal bonuses and margins.
Stock up 63.3% YTD, hitting $431.95 high.
Bullish Signals
Robert W. Baird upgraded Humana to Outperform and raised the price target to $596, reflecting strong confidence in the company's operational recovery.
The company achieved a significant milestone with 95% of Medicare Advantage members enrolled in 4.0-star or higher plans for 2027, up from 25% previously.
Analyst Michael Ha projects adjusted earnings per share to exceed $35 in 2028 due to conservative benefit designs and easing medical cost growth.
Restored Stars performance unlocks federal quality bonus payments that fund competitive member benefits and widen underwriting margins for Humana.
The stock has gained 63.3% year-to-date and reached a new 52-week high of $431.94, indicating strong market momentum.
Humana Inc. (NYSE: HUM) saw its stock surge approximately 15% in premarket trading following a significant improvement in its Medicare Advantage Star Ratings for the upcoming 2027 plan year. The company reported that 95% of its Medicare Advantage members are now enrolled in plans rated four stars or higher, a substantial increase from the previous year where only 20% of members held such ratings.
Specifically, Humana secured 4.5-star ratings for six contracts and four-star ratings for twelve others, exceeding last year's total by eleven contracts. Additionally, its prescription drug contract achieved a 4.5-star rating. These high scores are critical as they determine eligibility for quality-based bonus payments from the federal government, directly impacting the company's revenue potential.
The improved performance is driven by robust preventive care metrics, including 534,000 additional completed preventive visits and 663,000 more care opportunities compared to the prior year. Humana highlighted specific successes in screening programs, such as identifying 600 previously undetected breast cancers through overdue mammograms and detecting 17,000 cases of eye disease among diabetic patients, demonstrating tangible value to its member base.
📈 HUM stock rose ~15% premarket after improved Medicare Advantage Star Ratings for 2027.
⭐ 95% of HUM Medicare members now hold four-star or higher plans, up from 20%.
🏆 Six HUM contracts earned 4.5 stars and twelve earned four stars for upcoming enrollment.
💊 HUM's prescription drug contract received a 4.5-star rating boosting overall quality standing.
💰 Higher ratings increase HUM eligibility for federal quality-based bonus payments.
📈 Humana stock climbed roughly 15% in premarket trading after announcing improved Medicare Advantage Star Ratings for the 2027 plan year.
⭐ The company reported that 95% of its Medicare Advantage members are now enrolled in four-star or higher plans, up from just 20% a year ago.
🏆 Six Medicare Advantage contracts received 4.5-star ratings and twelve received four-star ratings for the upcoming enrollment period.
💊 Humana's prescription drug contract also earned a 4.5-star rating, contributing to its overall quality standing.
📅 Annual Medicare enrollment opens October 15, 2026, with new coverage taking effect on January 1, 2027.
🩺 Humana facilitated 534,000 additional preventive visits and 663,000 more completed care opportunities compared to the previous year.
🦷 Screening efforts identified 600 previously undetected breast cancers and 17,000 cases of eye disease among diabetic patients.
💰 Higher star ratings increase Humana's eligibility for quality-based bonus payments from the federal government.
📊 JPMorgan analysts had expected between 60% and 70% of members to be in four-star plans, but Humana significantly exceeded this expectation.
Bullish Signals
Stock surged 15% on improved Medicare Advantage Star Ratings.
95% of members now hold four-star or higher plans.
Secured 4.5-star ratings for six new contracts.
Drug contract earned 4.5-star rating reinforcing performance.
Added 534k preventive visits and 663k care opportunities.
Bullish Signals
Humana stock surged approximately 15% in premarket trading following the announcement of improved Medicare Advantage Star Ratings for 2027.
The company achieved a major milestone with 95% of its Medicare Advantage members enrolled in four-star or higher plans, compared to only 20% last year.
Humana secured 4.5-star ratings for six contracts and four-star ratings for twelve others, exceeding the previous year's total by eleven contracts.
The insurer's prescription drug contract earned a 4.5-star rating, reinforcing its strong performance across different plan types.
Humana reported 534,000 additional preventive visits and 663,000 more completed care opportunities than the prior year, demonstrating operational excellence.
Specific outreach efforts successfully identified 600 previously undetected breast cancers and 17,000 cases of eye disease among diabetic patients through screenings.
The improved star ratings directly enhance Humana's eligibility for quality-based bonus payments from the federal government, boosting potential revenue.
A securities fraud lawsuit against Humana Inc. (NYSE: HUM) and its former leadership has moved forward following a ruling by U.S. District Judge Jennifer L. Hall, who found that defendants acted with intent to defraud investors between July 2022 and October 2024.
The core allegations state that Humana misled shareholders regarding the company's exposure to rising costs associated with patients returning for medical care after the pandemic. This alleged deception caused the stock to trade at artificially inflated prices before the truth emerged in October 2024, coinciding with sharp declines in Star ratings across many of Humana's plans.
Following the revelation of these issues, Humana's stock price dropped by 22%. During the alleged period of misleading statements, insiders sold over $104 million worth of company stock. The firm Schubert Jonckheer & Kolbe is currently investigating potential wrongdoing by Humana's directors and officers in connection with these specific allegations.
Current shareholders are being advised that they may have legal options regarding this case. The investigation focuses on the conduct of corporate officers and directors, specifically concerning the false and misleading statements made to investors during the specified timeframe.
⚖️ Judge allows securities fraud lawsuit against Humana to proceed.
💸 Insiders sold over $104 million in Humana stock during alleged period.
📉 Humana stock fell 22% after cost exposure and rating declines revealed.
🔍 Law firm investigates potential wrongdoing by Humana directors and officers.
📉 A U.S. District Judge ruled that a securities fraud lawsuit against Humana will move forward after finding defendants acted with intent to defraud.
⚖️ The lawsuit alleges Humana misled investors about rising post-pandemic patient care costs between July 2022 and October 2024.
💸 Insiders sold over $104 million in Humana stock during the period of alleged misleading statements.
📉 Humana's stock price fell 22% after Star ratings declined and the truth about cost exposure was revealed in October 2024.
🔍 Schubert Jonckheer & Kolbe is investigating potential wrongdoing by Humana's directors and officers regarding these allegations.
Risk Factors
Judge found intent to defraud investors with false statements.
Misled shareholders on rising post-pandemic patient care costs.
Insiders sold $104M stock during alleged misleading period.
Stock dropped 22% after revelation and Star rating declines.
Risk Factors
A U.S. District Judge found that Humana acted with intent to defraud investors by making false and misleading statements between July 2022 and October 2024.
The company allegedly misled shareholders regarding its exposure to rising costs as patients returned for medical care after the pandemic.
Insiders sold over $104 million in Humana stock during the period when the company allegedly misled investors about cost exposures.
Humana's stock price dropped 22% following the revelation of misleading statements and sharp declines in Star ratings across its plans.
Humana Inc. (HUM) has entered into a distribution agreement with TempraMed Technologies Ltd. to distribute temperature-controlled medication storage products, specifically VIVI Cap® and VIVI Epi®, through its CenterWell Pharmacy branch. This partnership represents a strategic expansion for Humana's pharmacy network capabilities, aiming to enhance the management of temperature-sensitive medications for patients and healthcare providers within the US market.
The agreement allows TempraMed to leverage CenterWell's extensive distribution channels to increase its market presence in the United States. While the deal does not include guaranteed minimum orders and can be terminated with 60 days' notice, it signifies a significant step forward for commercial growth initiatives involving Humana's pharmacy division.
As of September 23, 2026, Humana Inc. shares are trading at USD 378.73, reflecting a slight 0.19% increase on the day. The company maintains a market capitalization of $45.46 billion and an enterprise value of $52.81 billion. Despite the positive nature of the TempraMed partnership, recent order activity on trading platforms remains predominantly sell-oriented at 81%, indicating cautious investor sentiment regarding the stock's immediate trajectory.
🤝 Humana signs distribution deal for VIVI Cap® and VIVI Epi® via CenterWell Pharmacy.
📈 Partnership expands temperature-sensitive medication management reach across US healthcare market.
💰 HUM shares trade at USD 378.73 with slight 0.19% daily increase.
🤝 Humana Inc. has signed a distribution deal with TempraMed Technologies to supply VIVI Cap® and VIVI Epi® products through its CenterWell Pharmacy branch.
📈 The partnership aims to expand the reach of temperature-sensitive medication management within Humana's US healthcare market presence.
💰 As of Sep 23, 2026, HUM shares are priced at USD 378.73 with a slight 1-day increase of 0.19%.
📊 The company reports a market capitalization of $45.46 billion and an enterprise value of $52.81 billion.
⚠️ Pluang order activity remains predominantly sell at 81%, highlighting cautious investor sentiment despite the new distribution agreement.
📝 The TempraMed agreement does not guarantee minimum orders and can be terminated with 60 days' notice.
Bullish Signals
Secured partnership with TempraMed to expand pharmacy network.
New CenterWell deal drives commercial growth in US.
Risk Factors
Pluang sell orders at 81% show cautious sentiment.
TempraMed deal lacks minimum orders and has 60-day exit.
Bullish Signals
Humana Inc. has secured a strategic distribution partnership with TempraMed Technologies to expand its pharmacy network's capabilities in managing temperature-sensitive medications.
The new agreement with CenterWell Pharmacy represents a significant step for commercial growth and market presence expansion within the US healthcare sector.
Risk Factors
Pluang order activity remains predominantly sell at 81%, indicating cautious investor sentiment despite the recent positive distribution deal announcement.
The TempraMed distribution agreement lacks guaranteed minimum orders and includes a termination clause allowing exit with only 60 days' notice, introducing potential revenue volatility.
Humana (NYSE:HUM) shares have surged approximately 48% over the past month, significantly outperforming peers UnitedHealth Group (UNH) and Cigna Group (CI). The rally is primarily driven by a favorable Medicare Advantage rate decision that lifted regulatory overhangs, combined with strong Q1 2026 financial results. Humana reported adjusted earnings per share of $10.31, beating the consensus estimate of $10.20, while revenue increased 24% year-over-year to $39.65 billion.
The company's insurance segment benefit ratio improved to 89%, surpassing internal guidance, and individual Medicare Advantage membership grew by 22% year-to-date. Management has affirmed full-year 2026 adjusted EPS guidance of at least $9 and revenue of at least $160 billion. CEO Jim Rechtin highlighted a solid start to the year, noting that operating execution is well-positioned for future growth.
Despite the strong momentum, analysts note that much of the regulatory relief may already be priced into the stock, with some suggesting Humana could be overvalued by 16% relative to a fair value near $213. The stock recently consolidated between $293 and $304 after opening at $301.11, indicating a potential pause in the rally as investors digest the magnitude of the recent gains.
Key upcoming catalysts include the October Stars ratings release and enrollment commentary, which will be critical for sustaining the recovery narrative. While operating cash flow surged 279% year-over-year to $1.254 billion in Q1, the long-term context shows Humana is still down 32% over the past five years, framing the current move as a significant recovery rally rather than the start of a new bull market.
📈 Stock rallied 48% in one month, outperforming peers.
💰 Q1 EPS beat consensus at $10.31 with 24% revenue growth.
🏥 Insurance benefit ratio improved to 89%, beating guidance.
Humana is exiting specific Medicare Advantage plans affecting approximately 600,000 members starting in 2027, with federally required non-renewal notices scheduled to arrive on October 2. The company stated this strategic move involves benefit adjustments and targeted exits to concentrate resources on higher-performing coverage while working toward its profitability goals.
Federal regulations provide a guaranteed-issue right for Medigap policies when an enrollee switches from Original Medicare due to a plan exit. This protection allows affected Humana members to purchase standardized plans like Plan G without medical underwriting or waiting periods, regardless of pre-existing conditions developed after joining the Advantage program.
Humana expects to recapture a meaningful share of these 600,000 members by moving them into other Humana offerings, though this is not automatic. Members must actively compare replacement plans for differences in physician networks, drug formularies, and out-of-pocket limits, or transition to Original Medicare plus Medigap before the annual enrollment period concludes.
📉 Humana exits Medicare Advantage for 600,000 members in 2027 to focus on higher-performing coverage.
📅 Non-renewal notices dated October 2 precede the October 15 annual enrollment period.
🛡️ Affected members receive guaranteed-issue rights for Medigap Plan G without medical underwriting.
💰 Company aims to retain members by moving them into other Humana offerings.
⚠️ Members must verify replacement plans include their specific doctors, drugs, and hospitals.
📉 Humana is exiting Medicare Advantage plans affecting approximately 600,000 members in 2027 as part of a strategy to focus on higher-performing coverage.
📅 Federally required non-renewal notices for these exits are dated October 2, giving members time to act before the annual enrollment period begins on October 15.
🛡️ Federal law grants affected Humana members a guaranteed-issue right to purchase Medigap Plan G or other standardized plans without medical underwriting when switching from Original Medicare.
💰 The company aims to retain many affected members by moving them into other Humana offerings, though this requires active selection and verification of new plan details.
⚠️ Members losing their current Humana Advantage coverage must verify that replacement plans include their specific doctors, drugs, and hospitals before making a decision.
Bullish Signals
Guaranteed-issue Medigap rights for members upon plan exit.
Plans to recapture 600,000 members via other offerings.
Risk Factors
Exiting Medicare Advantage plans affecting 600,000 members in 2027.
Strategy of concentrating on higher-performing coverage involves benefit adjustments.
Bullish Signals
Federal regulations provide Humana members with a guaranteed-issue right to purchase Medigap policies without medical underwriting or waiting periods when the company exits a plan.
Humana expects to recapture a meaningful share of the 600,000 affected members by moving them into other Humana offerings rather than losing them entirely.
Risk Factors
Humana is exiting Medicare Advantage plans affecting approximately 600,000 members in 2027, which will disrupt coverage for those who do not secure alternative plans.
The company's strategy of concentrating on higher-performing coverage involves benefit adjustments and targeted exits that may result in losing specific plan options members previously utilized.
As of September 16, 2026, Humana Inc. (HUM) trades at $396.62, trading below the consensus Wall Street price target of $415.00 set by 26 analysts and CleaRank Financial AI's fair value estimate. The stock exhibits neutral technical indicators with an RSI of 54 and is positioned above its 50-day moving average of $389.28, suggesting a balanced market sentiment without immediate extreme momentum.
Fundamental analysis highlights projected revenue growth of 26.00% for the current year and 4.00% for the following year, indicating strong top-line expansion potential. The company recently exceeded earnings per share (EPS) estimates for the quarter ending June 2026, demonstrating operational efficiency and the ability to deliver better-than-expected financial results.
Despite positive growth projections, HUM trades at a P/E ratio of 39.27, which is notably higher than the sector median of 31.9, suggesting the stock may be trading at a premium that could be difficult to sustain. The prevailing 'Hold' rating from the majority of Wall Street analysts reflects a balanced view, indicating limited immediate upside potential and a need for further positive catalysts to justify the current valuation.
Long-term simulations project significant variance in HUM's future performance, with a base case projecting a price near $537 by 2030 compared to an S&P 500 backtest showing underperformance over the last decade. While insider net purchases of $1.6 million signal confidence in future prospects, the high valuation and neutral analyst consensus suggest investors should exercise caution regarding immediate upside.
📈 HUM trades at $396.62 below $415 analyst target.
📊 Projected revenue growth is 26% this year and 4% next.
💰 Humana beat EPS estimates, showing operational efficiency.
⚠️ P/E ratio of 39.27 exceeds sector median of 31.9.
🔍 Insiders bought $1.6 million in stock recently.
📈 HUM trades at $396.62 as of September 16, 2026, below the consensus Wall Street price target of $415.00 across 26 analysts.
📊 The company projects strong revenue growth of 26.00% for the current year and 4.00% for the next year.
💰 Humana exceeded EPS estimates in the quarter ending June 2026, demonstrating operational efficiency.
⚠️ HUM's P/E ratio of 39.27 is significantly higher than the sector median of 31.9, indicating a potential valuation premium.
📉 The prevailing 'Hold' rating from Wall Street analysts suggests limited immediate upside potential and a need for further catalysts.
🔍 Insider activity shows net purchases totaling $1.6 million, signaling strong confidence in the company's future prospects.
📅 Technical indicators show an RSI of 54 in neutral territory with the price above its 50-day average of $389.28.
📉 Historical backtests indicate a $10,000 investment in HUM since September 2016 would be worth about $22,713 today versus $35,497 for the S&P 500.
Humana Inc. is projecting robust revenue growth of 26.00% for the current year and 4.00% for the next year, indicating strong top-line expansion.
The company exceeded EPS estimates in the quarter ending June 2026, demonstrating operational efficiency and the ability to deliver better-than-expected results.
Insiders have made net purchases totaling $1.6 million, signaling strong confidence in the company's future prospects.
Risk Factors
HUM trades at a P/E ratio of 39.27, which is notably higher than the sector median of 31.9, suggesting the stock may be trading at a premium that could be difficult to sustain.
The prevailing 'Hold' rating from a majority of Wall Street analysts indicates a balanced view, suggesting limited immediate upside potential and a need for further positive catalysts.
Humana Inc. (NYSE: HUM) reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, reaffirming full-year adjusted EPS guidance of at least $9.00 while lowering its FY 2026 GAAP EPS forecast to at least $6.52 due to non-cash adjustments and value creation charges. The company expects individual Medicare Advantage membership to grow approximately 25% in 2026, supported by strategic expansion of its CenterWell primary care business and a recent win in Illinois Medicaid. However, profitability faces headwinds from lower Star Ratings and elevated medical benefit ratios that reached 91.2% in the quarter.
HealthStream, Inc. (NASDAQ: HSTM) delivered record Q2 2026 results with revenue rising 12.5% year over year to $83.7 million and operating income increasing 41.4% to $8.3 million. The company maintains a debt-free balance sheet supported by $66.7 million in cash, while recurring subscription revenue grew 11.2%. HealthStream is leveraging strategic acquisitions like Virsys12 and MissionCare Collective to capture market share in workforce retention and compliance solutions, though it faces risks related to customer concentration and integration execution.
The article contrasts the two companies' trajectories, noting Humana's complex transition involving regulatory pressures versus HealthStream's operational cleanliness and higher growth profile. Hedge fund positioning shows increasing institutional participation in both stocks, with major funds like Pzena Investment Management holding significant positions in Humana and First Eagle increasing stakes in HealthStream. Investors are advised to watch for stabilization of medical cost ratios at Humana and sustained margin expansion from its SaaS model at HealthStream.
📈 Humana reaffirmed FY26 adjusted EPS guidance of at least $9.00.
📉 Humana lowered FY26 GAAP EPS forecast to at least $6.52.
👥 Humana expects 25% Medicare Advantage membership growth in 2026.
⚠️ Lower Star Ratings continue to drag on Humana's profitability.
🤝 Humana partners with HealthStream to expand rural caregiver training.
📈 Humana reported Q2 2026 GAAP EPS of $5.73 and adjusted EPS of $7.61, reaffirming full-year adjusted EPS guidance of at least $9.00.
📉 Humana lowered its FY 2026 GAAP EPS forecast to at least $6.52 from $8.36 reflecting non-cash adjustments and value creation charges.
👥 Humana expects individual Medicare Advantage membership to grow approximately 25% in 2026 alongside CenterWell primary care expansion.
⚠️ Lower Star Ratings remain a significant drag on Humana's profitability, with medical benefit ratios reaching 91.2% in Q2.
📈 HealthStream delivered record Q2 2026 results with revenue rising 12.5% year over year to $83.7 million.
💰 HealthStream operating income increased 41.4% to $8.3 million while net income climbed 23.8% to $6.7 million.
🛡️ HealthStream maintains a debt-free balance sheet supported by $66.7 million in cash and cash equivalents.
🔄 HealthStream recurring subscription revenue increased 11.2% in Q2, demonstrating strong SaaS model performance.
🤝 Humana announced a partnership with HealthStream to expand workforce training for caregivers in rural and underserved communities.
🏦 Pzena Investment Management holds 4,403,136 shares of Humana valued at approximately $1.75 billion.
📈 First Eagle Investment Management increased its position in HealthStream by 40% to hold 591,898 shares.
⚖️ Investors should watch for stabilization of medical cost ratios at Humana and successful integration of M&A at HealthStream.
Bullish Signals
Reaffirmed full-year adjusted EPS guidance of at least $9.00.
Individual Medicare Advantage membership expected to grow 25% in 2026.
CenterWell expansion and Illinois Medicaid win strengthen addressable market.
Risk Factors
Lower star ratings drag profitability and squeeze margins.
Medical benefit ratios hit 91.2% in Q2, pressuring earnings.
Regulatory pressures and star rating headwinds hurt future performance.
Bullish Signals
Humana reaffirmed its full-year adjusted EPS guidance of at least $9.00 despite lowering GAAP EPS forecasts due to non-cash adjustments.
Individual Medicare Advantage membership is expected to grow approximately 25% in 2026, supporting long-term recovery.
Strategic expansion of the CenterWell primary care business and a recent Illinois Medicaid win could strengthen the addressable market.
Risk Factors
Lower Star Ratings remain a significant drag on Humana's profitability, potentially squeezing margins further.
Elevated medical benefit ratios reached 91.2% in Q2, indicating ongoing pressure on net earnings.
Regulatory pressures in Medicaid and continued Medicare Star Ratings headwinds could weigh on future performance.
Humana Inc. (HUM) is highlighted as a strong hold for investors due to its robust value-based care model, strategic acquisitions, and the tailwinds of an aging U.S. population. The company has significantly outperformed its industry peers, with shares surging 55.7% year-to-date compared to the sector's 20.9% growth. Humana offers comprehensive health insurance through HMO, PPO, and FFS plans, alongside specialty products like dental and vision.
Financially, Humana demonstrates strong earnings consistency, beating estimates in four consecutive quarters with an average surprise of 9.6%. Its Medicare Advantage business serves as a primary growth engine, seeing membership expand 23.8% and premiums rise 26.4% year-over-year in the second quarter of 2026. The company is also leveraging its CenterWell subsidiary to integrate pharmacy and home health services, driving a 22.6% revenue increase for that segment.
Despite positive momentum, Humana faces headwinds including rising medical cost intensity which increased operating expenses to 96.7% of revenues in Q2 2026. The company carries a debt-laden balance sheet with $12 billion in long-term debt and a forward P/E ratio significantly higher than the industry average. However, Humana maintains a solid financial position with $23.9 billion in cash and investment securities, allowing for continued capital allocation toward growth initiatives and shareholder returns via dividends and buybacks.
UnitedHealth Group (UNH) and Humana (HUM) are leading a sector-wide rebound in April 2026, with both stocks rising approximately 4% to trade near $368 and $233 respectively. UnitedHealth has significantly outperformed Humana year-to-date, gaining 12% compared to Humana's decline of 9%, driven by strong fundamentals and a clear earnings beat in early April.
UnitedHealth reported Q1 2026 adjusted EPS of $7.23 against a consensus of $6.57, with revenue reaching $111.72 billion versus an estimate of $109.57 billion. The company improved its medical cost ratio to 84% and raised its full-year 2026 adjusted EPS outlook to over $18.25 while maintaining revenue guidance above $439 billion, signaling robust operational efficiency.
Humana's stock rally reflects a recovery from steep drawdowns linked to Q4 2025 earnings, which featured a sharp step-down in FY2026 guidance due to Star Ratings headwinds. However, the bullish case for Humana centers on individual Medicare Advantage growth of roughly 25% in 2026, with January membership increasing by approximately 1.03 million members.
The article highlights a strategic divergence between the two giants: UnitedHealth benefits from its diversified Optum unit and lower exposure to Medicare Advantage rate volatility, whereas Humana remains heavily concentrated in Medicare Advantage, making it more sensitive to regulatory rate decisions and Star Ratings fluctuations.
📉 Humana lowered FY2026 guidance to at least $9 due to Star Ratings headwinds.
👥 Humana grew individual Medicare Advantage membership by roughly 25% in 2026.
⚖️ Humana faces regulatory concentration risk from heavy reliance on Medicare Advantage.
📅 Humana reports Q1 2026 results on April 29 with high beat probability.
📈 UnitedHealth stock surged 36% since March while Humana gained 34%, with UNH leading the sector on price and fundamentals.
💰 UnitedHealth beat Q1 2026 earnings estimates with adjusted EPS of $7.23 versus $6.57 consensus and revenue of $111.72 billion.
📉 Humana stock is recovering from a steep drawdown following Q4 2025 results that lowered FY2026 guidance to at least $9 due to Star Ratings headwinds.
🏥 UnitedHealth improved its medical cost ratio to 84% and raised its 2026 adjusted EPS outlook to more than $18.25.
👥 Humana achieved roughly 25% growth in individual Medicare Advantage membership in 2026, with January additions of about 1,030,700 members.
🛡️ UnitedHealth's diversified Optum unit provides earnings stability that is less sensitive to Medicare Advantage rate notices compared to Humana.
⚖️ Humana faces higher concentration risk as its heavy reliance on Medicare Advantage exposes it to regulatory rate decisions and Star Ratings volatility.
📅 Humana is scheduled to report Q1 2026 results on April 29, with traders pricing a 76% probability of a beat based on management telegraphing 110% to 115% of full-year adjusted earnings.
🔮 Sector tailwinds include softer hospital volumes from peers and finalized 2% rate increases for 2027 Medicare Advantage payments benefiting both companies.
Bullish Signals
Stock rallied 4% to $233 reflecting recovery.
Medicare Advantage growth reached 25% in 2026.
Traders price 76% probability of beating Q1 2026.
Sector rally driven by softer hospital volumes.
Risk Factors
Heavy Medicare Advantage concentration increases regulatory exposure.
FY2026 guidance cut to $9 due to Star Ratings.
Drug pricing reform threatens core business model.
Bullish Signals
Humana stock rallied 4% in April to $233, reflecting a recovery from steep drawdowns linked to Q4 2025 earnings and stabilizing consumer-focused strategy.
Individual Medicare Advantage growth reached roughly 25% in 2026, with January membership increasing by approximately 1,030,700 members, validating the company's strategic pivot.
Polymarket traders are pricing a 76% probability that Humana will beat Q1 2026 earnings, supported by management guidance of 110% to 115% of full-year adjusted earnings for the quarter.
The broader managed care sector rebound is extending into April, with Humana participating in a group rally driven by softer hospital volumes and favorable rate environments.
Risk Factors
Humana remains heavily concentrated in Medicare Advantage, leaving its stock more exposed to regulatory rate decisions and Star Ratings volatility than diversified peers.
The company's Q4 2025 earnings report showed a sharp step-down in FY2026 guidance to at least $9, driven specifically by headwinds related to Star Ratings.
Humana faces regulatory risks regarding Medicare Advantage rates and potential drug pricing reform that could impact its core business model more severely than diversified competitors.
Humana (HUM) stock has plummeted over 20% in the past quarter, wiping out billions in market value following a disastrous earnings report where the company missed analyst estimates. The primary driver of this decline is a struggling Medicare Advantage business, which has stalled in enrollment and lost market share to peers. Goldman Sachs notes that while this segment was previously a growth engine, it now represents a significant risk, with 2023 revenue projections of $50 billion appearing increasingly optimistic.
The broader healthcare sector is also under pressure, with the S&P 500 Healthcare Index falling over 10% and competitors like UnitedHealth Group and Anthem seeing similar stock declines. Analysts cite concerns regarding the government's ability to pay for rising healthcare costs and the looming impact of the Affordable Care Act's individual mandate as key macroeconomic risks affecting Humana's margins and reimbursement rates.
In response to these challenges, Humana has announced plans to cut thousands of jobs in Louisville, Kentucky, to reduce costs and improve efficiency. This move is expected to negatively impact the local economy where the company is a major employer. While some analysts view the current stock price as a buying opportunity due to a 20% discount to peers, others remain cautious about the steep decline in the Medicare Advantage business and potential regulatory headwinds.
📉 Humana shares fell 20% after a $1.2 billion net loss.
✂️ Company plans thousands of job cuts in Louisville to save costs.
⚖️ Analysts are divided on stock value amid sector-wide declines.
📜 Regulatory risks threaten reimbursement rates and company margins.
📉 Humana shares have dropped over 20% in the last quarter after missing earnings estimates due to a net loss of $1.2 billion compared to a $1.5 billion profit a year ago.
🏥 Medicare Advantage enrollment has stalled, causing Humana's market share to lag behind peers and raising concerns about the sustainability of its primary growth strategy.
💰 Goldman Sachs previously estimated $50 billion in revenue for the Medicare Advantage business in 2023, but analysts now view these projections as overly optimistic given current trends.
📉 The broader healthcare sector is struggling with a S&P 500 Healthcare Index decline of over 10%, driven by fears that government finances are a 'ticking time bomb' for the industry.
✂️ Humana plans to cut thousands of jobs in Louisville, Kentucky, to reduce costs and improve efficiency amidst the company's financial downturn.
⚖️ Analysts are divided on the stock; Morgan Stanley sees it as attractive at a 20% discount to peers, while JPMorgan warns of steep declines in the core Medicare Advantage business.
📜 Regulatory risks loom large, specifically regarding the government's star ratings system which could profoundly impact reimbursement rates and fragile company margins.
🏛️ Macroeconomic concerns persist as investors worry about the government's ability to pay for rising healthcare costs and the potential impact of the Affordable Care Act's individual mandate.
Bullish Signals
Morgan Stanley sees 20% peer discount as attractive.
Net loss of $1.2 billion reverses prior year profit.
Medicare Advantage enrollment stalled causing revenue and share decline.
Government star ratings pressure margins and reimbursement rates.
Thousands of jobs cut in Louisville to reduce costs.
Analysts warn Medicare business steeply declines from estimates.
Bullish Signals
Some analysts, including Morgan Stanley, view Humana's stock as an attractive investment opportunity because it is currently trading at a 20% discount compared to its peers.
Goldman Sachs maintains that Humana's Medicare Advantage business remains a major source of growth for the company despite recent headwinds.
Risk Factors
Humana reported a net loss of $1.2 billion, a stark reversal from the $1.5 billion profit recorded in the same period last year.
Medicare Advantage enrollment has stalled, leading to a decline in revenue and causing Humana's market share to lag behind competitors.
The company faces intense pressure on margins due to the government's star ratings system, which can significantly impact reimbursement rates.
Humana has announced plans to cut thousands of jobs in Louisville, Kentucky, to reduce costs and improve operational efficiency.
Analysts express concern that Humana's Medicare Advantage business is in steep decline, with Morgan Stanley noting that previous revenue estimates are looking increasingly optimistic.
U.S. health insurer Humana has agreed to acquire home health-care and long-term care operator Kindred Healthcare for approximately $4 billion in a deal finalized on Tuesday. The transaction involves private-equity firms TPG Capital and Welsh, Carson, Anderson & Stowe, who will join Humana as co-buyers.
The consortium will pay $9 per share in cash, representing a 4.7 percent premium over Kindred's Friday closing price. Crucially, the deal includes a structural split of Kindred into two distinct units: one focused on home health care and hospice, and another for long-term acute care and rehabilitation.
Humana will acquire a 40 percent stake in the 'Kindred at Home' unit for $800 million, which employs 40,000 caregivers serving roughly 130,000 patients daily. Humana retains no ownership interest in the second Kindred unit containing acute care and rehabilitation assets.
This acquisition aligns with Humana's strategy to expand its Medicare-focused insurance business by integrating health providers into members' homes to improve outcomes and reduce costs. The move mirrors recent expansions by competitors Aetna and UnitedHealth into lower-cost care settings outside of hospitals.
🤝 Humana, TPG, and Welsh Carson acquire Kindred Healthcare for $4 billion.
💰 Deal values stock at $9/share, a 4.7% premium over Friday's close.
🔀 Transaction splits Kindred into home health and long-term acute care units.
🏠 Humana takes 40% stake in 'Kindred at Home' for $800 million.
🎯 Move supports strategy to improve Medicare outcomes via home-based providers.
🤝 Humana, TPG Capital, and Welsh, Carson, Anderson & Stowe agreed to acquire Kindred Healthcare for approximately $4 billion.
💰 The deal is valued at $9 per share in cash, marking a 4.7 percent premium over the stock's Friday close.
🔀 The transaction splits Kindred into two separate entities: one for home health/hospice and another for long-term acute care/rehabilitation.
🏠 Humana acquires a 40 percent stake in the 'Kindred at Home' unit for $800 million, gaining access to 40,000 caregivers.
👥 The acquired home health unit serves approximately 130,000 patients on a daily basis.
📉 Humana holds no equity stake in the second Kindred unit containing long-term acute care and rehabilitation assets.
🎯 This deal supports Humana's strategy to use home-based providers to improve health outcomes and save costs for its Medicare members.
🏆 The acquisition follows similar moves by competitors Aetna and UnitedHealth into non-hospital care locations.
Bullish Signals
Expands home health-care footprint to improve member outcomes.
Acquires 40% stake in Kindred with 40,000 caregivers.
Serves 130,000 daily patients through lower-cost care settings.
Bullish Signals
Humana expands its footprint in the home health-care sector, directly supporting its strategic focus on using providers in members' homes to improve health outcomes.
The acquisition of a 40 percent stake in Kindred at Home provides Humana with immediate access to a large network of 40,000 caregivers serving 130,000 daily patients.
The deal positions Humana competitively against peers like Aetna and UnitedHealth by establishing a significant presence in lower-cost care settings outside hospitals.
Andra AP fonden increased its position in Humana Inc. (NYSE:HUM) during the first quarter by purchasing 2,082 shares valued at approximately $361,000. This move adds to a broader trend of institutional activity, with other firms like Montag A & Associates and CoreCap Advisors also adjusting their stakes in the health insurance provider.
Analyst sentiment remains mixed but generally positive regarding valuation targets. Royal Bank of Canada raised its price target to $415.00, while Piper Sandler increased its objective to $254.00. The consensus average rating is currently a 'Hold' with a target price of $327.17, though the stock recently traded above these levels.
Humana reported strong financial results for the quarter ended April 29th, posting earnings per share of $10.31 against a consensus estimate of $9.97. Revenue reached $39.65 billion, representing a 23.5% year-over-year increase. The company has set full-year 2026 guidance for EPS between $9.00 and $9.46.
The Louisville-based insurer continues to focus on its core Medicare Advantage business and commercial plans. With a market capitalization of $47.35 billion and a P/E ratio of 42.18, the stock reflects investor expectations for continued growth in its senior-focused healthcare segment.
📈 Andra AP fonden bought 2,082 Humana shares worth ~$361k in Q1.
💰 Humana beat EPS estimates at $10.31 with $39.65B revenue (+23.5%).
🏦 Montag A & Associates holdings surged 1,880% while CoreCap rose 54.4%.
🎯 Royal Bank of Canada raised target to $415; consensus is 'Hold' at $327.17.
📅 FY 2026 EPS guidance set between $9.00 and $9.46 per share.
📈 Andra AP fonden purchased 2,082 shares of Humana Inc. valued at approximately $361,000 during the first quarter.
🏦 Montag A & Associates boosted holdings by 1,880% in Q4, while CoreCap Advisors increased its stake by 54.4%.
💰 Humana reported quarterly EPS of $10.31, beating analyst estimates of $9.97 by $0.34.
📊 Revenue for the quarter reached $39.65 billion, marking a significant 23.5% increase year-over-year.
🎯 Royal Bank of Canada raised its price target to $415.00 and maintained a 'sector perform' rating.
📉 The consensus analyst rating is currently 'Hold' with an average target price of $327.17.
📈 Humana's stock opened at $394.37, trading above its 50-day moving average of $362.43.
🏥 The company maintains a debt-to-equity ratio of 0.66 and a current ratio of 1.77.
📅 Humana has set FY 2026 EPS guidance between $9.00 and $9.46 per share.
👴 The insurer primarily serves seniors and Medicare-eligible populations across the United States.
Bullish Signals
EPS of $10.31 beat consensus estimate of $9.97.
Revenue surged 23.5% year-over-year to $39.65 billion.
Royal Bank of Canada raised price target to $415.
Piper Sandler increased objective to $254 from $182.
Debt-to-equity ratio stands at a healthy 0.66.
Risk Factors
Analysts rate the stock as Hold with limited upside.
High P/E of 42.18 limits appreciation if growth slows.
Bullish Signals
Humana reported quarterly earnings of $10.31 per share, surpassing the consensus estimate of $9.97 by $0.34.
Revenue grew significantly by 23.5% year-over-year to reach $39.65 billion for the quarter.
Royal Bank of Canada increased its price target to $415.00, indicating strong institutional confidence in valuation.
Piper Sandler raised its price objective to $254.00 from a previous level of $182.00.
The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.66 and a current ratio of 1.77.
Stock price is trading above both its 50-day moving average ($362.43) and 200-day moving average ($264.14).
Multiple institutional investors, including Andra AP fonden and Montag A & Associates, have recently increased their stakes.
Risk Factors
The consensus analyst rating is currently 'Hold', suggesting analysts are cautious about immediate upside potential.
The stock trades at a high price-to-earnings ratio of 42.18, which may limit near-term appreciation if growth slows.
Zacks Research has raised its Q4 2026 earnings per share (EPS) estimate for Humana Inc. to $6.07, up from a previous forecast of $6.08, maintaining a 'Strong-Buy' rating. The consensus full-year EPS estimate stands at $9.53, with Zacks also projecting Q4 2027 earnings at $1.91. This analyst upgrade follows a period of significant movement in broker price targets and ratings for the health insurance provider.
Humana recently reported strong financial results for the quarter ended April 29th, posting EPS of $10.31 which beat the consensus estimate of $9.97 by $0.34. The company generated revenue of $39.65 billion, exceeding analyst expectations of $39.37 billion, with year-over-year revenue growth of 23.5%. Key financial metrics included a net margin of 0.82%, a return on equity of 10.45%, and the company has set its FY 2026 guidance at $9.00 EPS.
Market sentiment remains mixed among major brokerages, with Goldman Sachs raising its price target to $195 while maintaining a 'sell' rating, contrasted by upgrades from JPMorgan Chase, Sanford Bernstein, and Wolfe Research which have issued higher price objectives or strong-buy ratings. The stock currently trades at an average analyst target of $325.87 based on MarketBeat data, with the firm holding a market capitalization of $48.09 billion.
Institutional ownership has seen notable increases in the fourth quarter, with Vanguard Group growing its stake by 0.7% to own over 14 million shares valued at approximately $3.65 billion. Other significant holders like Capital International Investors and Massachusetts Financial Services Co. also increased their positions substantially, indicating continued institutional interest despite the varied analyst ratings.
💰 Q1 FY2026 EPS hit $10.31, beating consensus by $0.34.
📈 Revenue reached $39.65B with 23.5% year-over-year growth.
🎯 Goldman Sachs raised price target to $195 but keeps 'sell'.
🏦 Vanguard increased stake to 14.26M shares valued at $3.65B.
📅 Full-year 2026 earnings guidance set at $9.00 per share.
📈 Zacks Research raised Q4 2026 EPS estimates to $6.07 from $6.08 and maintains a 'Strong-Buy' rating on Humana.
💰 The company reported Q1 FY2026 EPS of $10.31, beating analyst consensus of $9.97 by $0.34.
📊 Revenue reached $39.65 billion, surpassing estimates of $39.37 billion with 23.5% year-over-year growth.
🎯 Goldman Sachs raised its price target to $195 but retains a 'sell' rating on the stock.
📈 JPMorgan Chase increased its price objective from $214 to $316 while assigning a 'neutral' rating.
🏦 Vanguard Group increased its stake by 0.7% in Q4, now holding 14.26 million shares valued at $3.65 billion.
📉 Capital International Investors raised its position by 113.9%, adding over 3 million shares to its portfolio.
🏢 Massachusetts Financial Services Co. boosted its holdings by 28.9% in the fourth quarter.
📅 Humana has set full-year 2026 earnings guidance at $9.00 per share.
📉 The stock trades with a P/E ratio of 42.84 and a market capitalization of $48.09 billion.
Bullish Signals
Zacks upgraded Q4 2026 EPS forecast to $6.07.
Humana beat earnings by $0.34 and revenue by $280M.
Revenue grew 23.5% YoY to $39.65 billion.
Major investors like Vanguard increased stakes significantly in Q4.
JPMorgan raised price target to $316 with confidence.
ROE reached 10.45% with quick and current ratios at 1.77.
Risk Factors
Goldman Sachs maintains a sell rating on Humana.
High P/E ratio of 42.84 suggests overvaluation risks.
Mixed analyst sentiment with 15 holds and 2 sells.
Bullish Signals
Zacks Research upgraded its Q4 2026 EPS forecast to $6.07, reflecting improved analyst expectations for the company's profitability.
Humana beat quarterly earnings estimates by $0.34 per share and revenue estimates by $280 million, demonstrating strong operational execution.
Revenue grew 23.5% year-over-year to $39.65 billion, indicating robust demand for the company's Medicare Advantage and commercial plans.
Major institutional investors including Vanguard, Capital International, and Massachusetts Financial Services increased their stakes significantly in Q4.
JPMorgan Chase raised its price target by over $100 to $316, signaling confidence in the stock's long-term value despite a neutral rating.
The company achieved a return on equity of 10.45% and maintained healthy liquidity ratios with both quick and current ratios at 1.77.
Risk Factors
Goldman Sachs maintains a 'sell' rating on Humana despite raising its price target, suggesting concerns about valuation or competitive positioning.
The stock carries a high P/E ratio of 42.84, which may indicate that the market is pricing in significant future growth expectations.
Analyst ratings are split, with 15 analysts holding a 'Hold' rating and two issuing a 'Sell', creating mixed sentiment around the current price.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)